Discovery of Cell-Permeable Macrocyclic CyclinA/B RxL Inhibitors that Demonstrate Antitumor Activity

Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with Rb-deficiency or hyperactivated E2F

Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors

Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: selective inhibitors of the RxL binding site of cyclin family proteins

Journal of Medicinal Chemistry_Orally Bioavailable Macrocyclic Peptide Cyclin A_B RxL Inhibitors to Treat Cancers with High E2F Activity_J. Shapiro

AACR-NCI-EORTC CCND1 Poster

AACR25_CMayoh_Poster_CirclePharma_final

https://www.nature.com/articles/s41586-025-09433-w

Journal of Medicinal Chemistry: Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity